U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H14O3
Molecular Weight 242.2699
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOPROFEN

SMILES

CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1

InChI

InChIKey=RDJGLLICXDHJDY-UHFFFAOYSA-N
InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula C15H14O3
Molecular Weight 242.2699
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/fenoprofen.html

Fenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect. Indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
NALFON

Approved Use

NALFON is a nonsteroidal anti-inflammatory drug indicated for: • Relief of mild to moderate pain in adults. • Relief of the signs and symptoms of rheumatoid arthritis. • Relief of the signs and symptoms of osteoarthritis.

Launch Date

1.95696001E11
Primary
NALFON

Approved Use

NALFON is a nonsteroidal anti-inflammatory drug indicated for: • Relief of mild to moderate pain in adults. • Relief of the signs and symptoms of rheumatoid arthritis. • Relief of the signs and symptoms of osteoarthritis.

Launch Date

1.95696001E11
Primary
NALFON

Approved Use

NALFON is a nonsteroidal anti-inflammatory drug indicated for: • Relief of mild to moderate pain in adults. • Relief of the signs and symptoms of rheumatoid arthritis. • Relief of the signs and symptoms of osteoarthritis.

Launch Date

1.95696001E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
28.3 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105.2 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Disc. AE: Reaction gastrointestinal, Reaction skin...
Other AEs: Dyspepsia, Nausea...
AEs leading to
discontinuation/dose reduction:
Reaction gastrointestinal (2%)
Reaction skin (1%)
Cardiovascular disorder (NOS) (0.5%)
Other AEs:
Dyspepsia (10%)
Nausea (7.7%)
Constipation (7%)
Vomiting (2.6%)
Abdominal pain (2%)
Diarrhea (1.8%)
Headache (8.7%)
Somnolence (8.5%)
Dizziness (6.5%)
Tremor (2.2%)
Confusion (1.4%)
Sweating increased (4.6%)
Pruritus (4.2%)
Rash (3.7%)
Tinnitus (4.5%)
Blurred vision (2.2%)
Hearing decreased (1.6%)
Palpitations (2.5%)
Nervousness (5.7%)
Asthenia (5.4%)
Peripheral edema (5%)
Dyspnea (2.8%)
Fatigue (1.7%)
Upper respiratory infection (1.5%)
Nasopharyngitis (1.2%)
Gastritis (<1%)
Ulcer peptic with perforation (<1%)
Ulcer peptic with perforation (<1%)
Gastrointestinal hemorrhage (<1%)
Anorexia (<1%)
Flatulence (<1%)
Dry mouth (<1%)
Blood in stool (<1%)
Alkaline phosphatase increased (<1%)
LDH increased (<1%)
SGOT increased (<1%)
Jaundice (<1%)
Cholestatic hepatitis (<1%)
Buccal mucosa aphthous ulceration (<1%)
Taste metallic (<1%)
Pancreatitis (<1%)
Atrial fibrillation (<1%)
Pulmonary edema (<1%)
Electrocardiogram change (<1%)
Supraventricular tachycardia (<1%)
Renal failure (<1%)
Dysuria (<1%)
Cystitis (<1%)
Hematuria (<1%)
Oliguria (<1%)
Azotemia (<1%)
Anuria (<1%)
Nephritis interstitial (<1%)
Nephrosis (<1%)
Acute papillary necrosis (<1%)
Angioedema (<1%)
Purpura (<1%)
Bruising (<1%)
Hemorrhage (<1%)
Thrombocytopenia (<1%)
Hemolytic anemia (<1%)
Aplastic anemia (<1%)
Agranulocytosis (<1%)
Pancytopenia (<1%)
Depression (<1%)
Disorientation (<1%)
Seizures (<1%)
Trigeminal neuralgia (<1%)
Burning tongue (<1%)
Diplopia (<1%)
Optic neuritis (<1%)
Exfoliative dermatitis (<1%)
Toxic epidermal necrolysis (<1%)
Stevens-Johnson syndrome (<1%)
Alopecia (<1%)
Anaphylaxis (<1%)
Urticaria (<1%)
Malaise (<1%)
Insomnia (<1%)
Tachycardia (<1%)
Personality change (<1%)
Lymphadenopathy (<1%)
Mastodynia (<1%)
Fever (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Cardiovascular disorder (NOS) 0.5%
Disc. AE
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Reaction skin 1%
Disc. AE
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Nasopharyngitis 1.2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Confusion 1.4%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Upper respiratory infection 1.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Hearing decreased 1.6%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Fatigue 1.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Diarrhea 1.8%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Dyspepsia 10%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Abdominal pain 2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Reaction gastrointestinal 2%
Disc. AE
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Blurred vision 2.2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Tremor 2.2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Palpitations 2.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Vomiting 2.6%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Dyspnea 2.8%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Rash 3.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Pruritus 4.2%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Tinnitus 4.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Sweating increased 4.6%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Peripheral edema 5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Asthenia 5.4%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Nervousness 5.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Dizziness 6.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Constipation 7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Nausea 7.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Somnolence 8.5%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Headache 8.7%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Acute papillary necrosis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Agranulocytosis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Alkaline phosphatase increased <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Alopecia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Anaphylaxis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Angioedema <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Anorexia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Anuria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Aplastic anemia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Atrial fibrillation <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Azotemia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Blood in stool <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Bruising <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Buccal mucosa aphthous ulceration <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Burning tongue <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Cholestatic hepatitis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Cystitis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Depression <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Diplopia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Disorientation <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Dry mouth <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Dysuria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Electrocardiogram change <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Exfoliative dermatitis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Fever <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Flatulence <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Gastritis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Gastrointestinal hemorrhage <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Hematuria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Hemolytic anemia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Hemorrhage <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Insomnia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Jaundice <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
LDH increased <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Lymphadenopathy <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Malaise <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Mastodynia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Nephritis interstitial <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Nephrosis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Oliguria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Optic neuritis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Pancreatitis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Pancytopenia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Personality change <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Pulmonary edema <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Purpura <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Renal failure <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
SGOT increased <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Seizures <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Stevens-Johnson syndrome <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Supraventricular tachycardia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Tachycardia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Taste metallic <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Thrombocytopenia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Toxic epidermal necrolysis <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Trigeminal neuralgia <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Ulcer peptic with perforation <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Ulcer peptic with perforation <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
Urticaria <1%
400 mg 3 times / day steady, oral
Recommended
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy
n = 6786
Health Status: unhealthy
Condition: rheumatoid arthritis| osteoarthritis
Population Size: 6786
Sources:
PubMed

PubMed

TitleDatePubMed
[Study on the release mechanism of fenoprofen calcium from hydrophillic sustained-release matrix].
2001 Jan
Dehydration, hydration behavior, and structural analysis of fenoprofen calcium.
2001 Jul
Chiral inversion of (R)-(-)-fenoprofen in guinea-pigs pretreated with clofibrate.
2002 Jun
Physical stability and solubility of the thermotropic mesophase of fenoprofen calcium as pure drug and in a tablet formulation.
2002 Oct 24
Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada.
2003 Dec
Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography-tandem mass spectrometry.
2003 Dec 22
Enhancement of selectivity and resolution in the enantioseparation of uncharged compounds using mixtures of oppositely charged cyclodextrins in capillary electrophoresis.
2003 Jan
Capillary electrophoresis with laser induced-fluorescence detection of profens derivatized with the water-soluble fluorogenic reagent 4-N-(4-N'-aminoethyl)piperazino-7-nitro-2,1,3-benzoxadiazole.
2003 Sep 5
Application of capillary electrophoresis with different sample stacking strategies for the determination of a group of nonsteroidal anti-inflammatory drugs in the low microg x L(-1) concentration range.
2004 Feb
Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen.
2004 Nov
Cationic vesicles as chiral selector for enantioseparations of nonsteroidal antiinflammatory drugs by micellar electrokinetic chromatography.
2004 Sep 3
Using terahertz pulsed spectroscopy to quantify pharmaceutical polymorphism and crystallinity.
2005 Apr
Effects of non-ionic surfactants on isotachophoretic separations of 2-arylpropionic acids.
2005 Aug 19
Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery.
2005 Jan 25
Synthesis of fenoprofen and gemfibrozil styrene-maleic acid copolymer conjugates.
2005 Jun
Determination of nonsteroidal antiinflammatory drugs in water samples using liquid chromatography coupled with diode-array detector and mass spectrometry.
2005 Nov
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population.
2005 Nov 29
Optimization of gas chromatographic method for the enantioseparation of arylpropionic non-steroidal anti-inflammatory drug methyl esters.
2005 Sep 15
Different sample stacking strategies to analyse some nonsteroidal anti-inflammatory drugs by micellar electrokinetic capillary chromatography in mineral waters.
2006 Jun 9
Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment.
2006 Oct
Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River.
2006 Sep
Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.
2007 Dec
A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives.
2007 Dec 26
Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses.
2007 Jan
A peripatetic pediatrician's journey into pediatric rheumatology: Part II.
2007 Jun 21
Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY.
2007 Mar
Fenoprofen and ketoprofen amides as potential antitumor agents.
2007 Mar
Enantioseparation by CE with vancomycin as chiral selector: Improving the separation performance by dynamic coating of the capillary with poly(dimethylacrylamide).
2007 Mar
Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction?
2007 May
Rapid online-SPE-MS/MS method for ketoprofen determination in dermal interstitial fluid samples from rats obtained by microdialysis or open-flow microperfusion.
2007 May 1
Stereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumatoid arthritis.
2007 May 5
Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant.
2007 Nov
Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis.
2008
A combination of statistical and analytical evaluation methods as a new optimization strategy for the quantification of pharmaceutical residues in sewage effluent.
2008 Apr 21
Chiral separation of fluvastatin enantiomers by capillary electrophoresis.
2008 Aug
The effect of piroxicam on the formation of postoperative, intraabdominal adhesion in rats.
2008 Oct
Robust open tubular layer of S-ketoprofen imprinted polymer for chiral LC separation.
2008 Sep
Evaluation of pharmaceuticals and personal care products as water-soluble molecular markers of sewage.
2008 Sep 1
Chemoenzymatic and microbial dynamic kinetic resolutions.
2009 Apr
Combined use of chiral ionic liquid and CD for MEKC: Part II. Determination of binding constants.
2009 Aug
The novel phosphoramidate derivatives of NSAID 3-hydroxypropylamides: synthesis, cytostatic and antiviral activity evaluations.
2009 Jan
Synthesis and biological evaluation of O-methyl and O-ethyl NSAID hydroxamic acids.
2009 Oct
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.
2009 Sep
The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease.
2010
PPARs in Irradiation-Induced Gastrointestinal Toxicity.
2010
Rapid simultaneous determination of four non-steroidal anti-inflammatory drugs by means of derivative nonlinear variable-angle synchronous fluorescence spectrometry.
2010 Aug
A protein-coated magnetic beads as a tool for the rapid drug-protein binding study.
2010 Jul 8
Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe2+ chelating activity.
2010 Sep
Electrokinetic supercharging focusing in capillary zone electrophoresis of weakly ionizable analytes in environmental and biological samples.
2010 Sep
Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping.
2010 Sep 16
Patents

Sample Use Guides

In Vivo Use Guide
400 mg to 600 mg orally 3 or 4 times a day -Maximum dose: 3200 mg/day
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:40:57 UTC 2023
Edited
by admin
on Wed Jul 05 23:40:57 UTC 2023
Record UNII
RA33EAC7KY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENOPROFEN
HSDB   INN   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
(±)-M-PHENOXYHYDRATROPIC ACID
Systematic Name English
NSC-757813
Code English
FENOPROFEN [VANDF]
Common Name English
3-Phenoxyhydratropic acid
Systematic Name English
fenoprofen [INN]
Common Name English
FENOPROFEN [MI]
Common Name English
BENZENEACETIC ACID, .ALPHA.-METHYL-3-PHENOXY-
Systematic Name English
2-(M-PHENOXYPHENYL)PROPIONIC ACID
Systematic Name English
FENOPROFEN [HSDB]
Common Name English
FENOPROFEN [USAN]
Common Name English
DL-2-(3-PHENOXYPHENYL)PROPIONIC ACID
Common Name English
(±)-FENOPROFEN
Common Name English
Fenoprofen [WHO-DD]
Common Name English
2-(3-PHENOXYPHENYL)PROPIONIC ACID
Systematic Name English
LILLY-53858
Code English
Classification Tree Code System Code
NCI_THESAURUS C1323
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
WHO-ATC M01AE04
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
WHO-VATC QM01AE04
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
NDF-RT N0000175721
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
NDF-RT N0000175722
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
LIVERTOX NBK547969
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
NDF-RT N0000000160
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
Code System Code Type Description
HSDB
3328
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
WIKIPEDIA
FENOPROFEN
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
CAS
31879-05-7
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
SUPERSEDED
PUBCHEM
3342
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
EVMPD
SUB07578MIG
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
ECHA (EC/EINECS)
249-770-1
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
SMS_ID
100000081301
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
DRUG BANK
DB00573
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
INN
3104
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
ChEMBL
CHEMBL1297
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
NCI_THESAURUS
C61760
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
LACTMED
Fenoprofen
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
EPA CompTox
DTXSID9023045
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
NSC
757813
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
FDA UNII
RA33EAC7KY
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
CAS
29679-58-1
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
CHEBI
5004
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
ECHA (EC/EINECS)
250-850-3
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
ALTERNATIVE
DRUG CENTRAL
1154
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
MESH
D005279
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
MERCK INDEX
M5281
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY Merck Index
RXCUI
4331
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY RxNorm
IUPHAR
4820
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
DAILYMED
RA33EAC7KY
Created by admin on Wed Jul 05 23:40:57 UTC 2023 , Edited by admin on Wed Jul 05 23:40:57 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC